A New Combination of Factor XA Inhibition and Standard Antiplatelet Therapy to Prevent More Recurrent Cardiovascular Events in Acute Coronary Syndrome (ACS) - European Medical Journal
×

Browse

A New Combination of Factor XA Inhibition and Standard Antiplatelet Therapy to Prevent More Recurrent Cardiovascular Events in Acute Coronary Syndrome (ACS)

| Download as | PDF
Speakers:
Christoph Bode,1 Gabriel Steg,2 Gilles Montalescot,3 Robert Welsh4
Disclosure:

The speakers were contracted by EuroPCR to participate in this satellite symposium.

Acknowledgements:

Writing assistance provided by Trilogy Writing and Consulting Ltd.

Support:

The publication of this article was funded by Bayer HealthCare Pharmaceuticals. The views and opinions expressed are those of the authors and not necessarily of Bayer.

Citation
EMJ Int Cardiol. ;1[1]:20-33.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Meeting Summary

The purpose of this symposium was to:

  • Discuss the interplay between the coagulation cascade and platelets in arterial thrombus formation.
  • Present the rationale for oral antiplatelet and anticoagulant therapy to reduce residual thrombotic risk in patients following Acute Coronary Syndrome (ACS).
  • Discuss the significant benefits seen in patients following ACS when combining rivaroxaban 2.5 mg twice daily with standard antiplatelet therapy.
  • Assess how the use of oral anticoagulation may change current standards of care and influence guidelines in patients with ACS.

Receive our free quarterly newsletters and your choice of journal publication alerts, straight to your inbox.

Join our mailing list

Please view the full content in the pdf above.